Login to Your Account

Elusys Wins $143M BARDA Pact to Advance its Anthrax Antitoxin

By Donna Young

Tuesday, December 29, 2009
WASHINGTON - Elusys Therapeutics Inc. won a five-year contract potentially worth $143 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the company's inhalational anthrax antitoxin Anthim, a high-affinity deimmunized monoclonal antibody. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription